

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4456047

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NAVIDEA BIOPHARMACEUTICALS, INC.	03/03/2017
RECEIVING PARTY DATA	
Name:	CARDINAL HEALTH 414, LLC
Street Address:	7000 CARDINAL PLACE
City:	DUBLIN
State/Country:	OHIO
Postal Code:	43017
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	15326965
Application Number:	15326985
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	patent@cardinalhealth.com
Correspondent Name:	CARDINAL HEALTH
Address Line 1:	1500 WAUKEGAN ROAD
Address Line 2:	ATTN: KIM LUNA
Address Line 4:	WAUKEGAN, ILLINOIS 60085
ATTORNEY DOCKET NUMBER:	170038/US-ORD1&2
NAME OF SUBMITTER:	ADNAN H. BOHRI
SIGNATURE:	/ADNAN H. BOHRI/
DATE SIGNED:	06/12/2017
Total Attachments: 6	
source=170038 _1_Patent Assignment #page1.tif	
source=170038 _1_Patent Assignment #page2.tif	
source=170038 _1_Patent Assignment #page3.tif	
source=170038 _1_Patent Assignment #page4.tif	
source=170038 _1_Patent Assignment #page5.tif	

Patent Assignment

This PATENT ASSIGNMENT, dated as of March 3, 2017 (this "Patent Assignment"), is executed and delivered by Navidea Biopharmaceuticals, Inc., a Delaware corporation ("Assignor"), in favor of Cardinal Health 414, LLC, a Delaware limited liability company ("Assignee").

RECITALS

A. Assignor and Assignee entered into that certain Asset Purchase Agreement, dated as of November 23, 2016 (the "Asset Purchase Agreement"), pursuant to which, at the Closing, Assignor has agreed to sell, transfer, convey and assign to Assignee, and Assignee has agreed to purchase and assume from Seller, Assignor's worldwide right, title and interest in, to and under, along with other Acquired Assets, the patents and patent applications, reexaminations, extensions and counterparts claiming priority therefrom set forth on Schedule A hereto, and any other indicia of invention ownership issued or granted by a Governmental Authority, applications for any of the foregoing, including provisional, utility, design, priority and other applications, divisionals, and continuations (in whole or in part) and reissues or re-examinations of any of the foregoing (hereinafter collectively referred to as the "Patents");

B. In accordance with the Asset Purchase Agreement, Assignor desires to sell, transfer, convey and assign to Assignee, and Assignee desires to purchase and assume all of Assignor's worldwide right, title and interest in, to and under the Patents and in and to the inventions represented thereby;

C. Capitalized terms used herein without definition shall have the respective meanings set forth in the Asset Purchase Agreement.

NOW, THEREFORE, in consideration of the foregoing premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and with the intent to be legally bound hereby, Assignor and Assignee agree as follows:

AGREEMENT

Assignor hereby sells, transfers, conveys and assigns to Assignee, its successors and assigns all of Assignor's right, title and interest in, to and under the Patents and all rights to the inventions described and claimed therein, together with the right to claim priority in all foreign countries in accordance with international Legal Requirements, any and all rights corresponding to Patents in foreign countries throughout the world and all of Assignor's rights and actions for past infringement and/or misappropriation, all to be held and enjoyed by Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor had this Patent Assignment not been made.

Assignee agrees to execute and deliver, or cause to be executed and delivered, such further instruments and take such other actions as Assignee or Assignor may deem reasonably necessary to record the assignment of the Patents to Assignee as contemplated by this Patent Assignment.

Assignor authorizes and requests that the United States Commissioner of Patents and Trademarks and any other similar government authority to record Assignee as owner of the Patents and issue any and all patents issued thereon to Assignee, as assignee of the entire right, title and interest in, to and under the same, for the sole use and enjoyment of Assignee and its successors, assigns or other legal representatives. Assignee shall have the right to record this Patent Assignment with all applicable government authorities and registrars so as to perfect its ownership of the Patents.

This Patent Assignment shall inure to the benefit of and be binding upon the parties hereto and their respective successors and permitted assigns.

This Patent Assignment may be executed in two or more counterparts for the convenience of the parties, each of which will be deemed an original and all of which together will constitute one and the same instrument. Delivery of an executed counterpart of a signature page to this Patent Assignment by facsimile or portable document format will be effective as delivery of a manually executed counterpart to this Patent Assignment.


This Patent Assignment will be governed by, and construed in accordance with, the internal Legal Requirements of the State of Delaware, without reference to the choice of Legal Requirement or conflict of Legal Requirements principles thereof. The parties hereby agree and consent to be subject to the exclusive jurisdiction of the courts of Delaware, and hereby waive the right to assert the lack of personal or subject matter jurisdiction or improper venue in connection with any such Action.

This Patent Assignment is being executed and delivered pursuant to Section 2.9(a) of the Asset Purchase Agreement and is not intended to in any way supersede, amend, expand, waive or otherwise modify or affect the rights and obligations of the parties under the Asset Purchase Agreement.

[signature page follows]

IN WITNESS WHEREOF, Assignor and Assignee have caused this Patent Assignment to be executed as of the date first written above.

NAVIDEA BIOPHARMACEUTICALS, INC.

By: 
Name: Jed A. Latkin
Title: Interim Chief Financial Officer/Chief Operating Officer

CARDINAL HEALTH 414, LLC

By: _____
Name: _____
Title: _____

[Signature Page to Patent Assignment]

IN WITNESS WHEREOF, Assignor and Assignee have caused this Patent Assignment to be executed as of the date first written above.

NAVIDEA BIOPHARMACEUTICALS, INC.

By: _____
Name: _____
Title: _____

CARDINAL HEALTH 414, LLC

By: Tiffany Olson
Name: Tiffany Olson
Title: President - Nuclear Pharmacy Services

[Signature Page to Patent Assignment]

Schedule A
Patents

Country Name	Application No.	Filing Date	Pub. No.	Pub. Date	Patent Number	Issue Date	Application Status	Title	Inventor
United States of America	13/461306	5/1/2012	US 2012-0213700	8/23/2012	8545808	10/1/2013	Granted	Compositions for Radiolabeling Diethyleneritraminepentacetic Acid (DTPA)-Dextran	Gerald Ross Magnuson; Richard Cushman Oralhood
United States of America	14/039648	9/27/2013	US 2014-0023586	1/23/2014	9439985	9/13/2016	Granted	Compositions for Radiolabeling Diethyleneritraminepentacetic Acid (DTPA)-Dextran	Gerald Ross Magnuson; Richard Cushman Oralhood
United States of America	15/233144	8/10/2016	US 2016-0347679	12/1/2016			Published	Compositions for Radiolabeling Diethyleneritraminepentacetic Acid (DTPA)-Dextran	Gerald Ross Magnuson; Richard Cushman Oralhood
Canada	2750230	7/20/2011	2750230	8/5/2010			Published	Compositions for Radiolabeling Diethyleneritraminepentacetic Acid (DTPA)-Dextran	Gerald Ross Magnuson; Richard Cushman Oralhood
Patent Cooperation Treaty	PCT/US10/00222	1/28/2010	WO 2010/087959	1/28/2010			Nationalized	Compositions for Radiolabeling Diethyleneritraminepentacetic Acid (DTPA)-Dextran	Gerald Ross Magnuson; Richard Cushman Oralhood

United States of America	14/338332	7/22/2014	US 2015-0023876	1/22/2015			Published	Compositions, Methods and Kits for Diagnosing and Treating CD206 Expressing Cell-Related Disorders	Fred Cope, Wendy Metz, Mike Blue; Larry Schlesinger
Canada	2918782	7/22/2014	2918782	1/29/2015			Published	Compositions, Methods and Kits for Diagnosing and Treating CD206 Expressing Cell-Related Disorders	Fred Cope, Wendy Metz, Mike Blue; Larry Schlesinger
China (People's Republic)	201480051858.9	7/22/2014	105764529	7/13/2016			Published	Compositions, Methods and Kits for Diagnosing and Treating CD206 Expressing Cell-Related Disorders	Fred Cope, Wendy Metz, Mike Blue; Larry Schlesinger
Patent Cooperation Treaty	PCT/US2014/047708	7/22/2014	WO 2015/013341	1/29/2015			Nationalized	Compositions, Methods and Kits for Diagnosing and Treating CD206 Expressing Cell-Related Disorders	Fred Cope, Wendy Metz, Mike Blue; Larry Schlesinger

Country Name	Application No.	Filing Date	Pub. No.	Pub. Date	Patent Number	Issue Date	Application Status	Title	Inventor

United States of America	62/404111	10/4/2016					Pending	Compositions and Methods for Diagnosing and Treating Macrophage-Related Disorders Using Carbodiyrate-Based Macromolecular Carrier	Fred Cope
--------------------------	-----------	-----------	--	--	--	--	---------	---	-----------

United States of America	14/803010	7/17/2015	2016-0206763	7/21/2016			Published	Compounds and Compositions for Targeting Macrophages and other Mannose-Binding C-Type Lectin Receptor High Expressing Cells and Methods of Treating and Diagnosis Using Same.	Fred Cope
Patent Cooperation Treaty	PCT/US2015/041036	7/17/2015	WO 2016/118188	7/28/2016			Published	Compounds and Compositions for Targeting Macrophages and other Mannose-Binding C-Type Lectin Receptor High Expressing Cells and Methods of Treating and Diagnosis Using Same.	Fred Cope
Patent Cooperation Treaty	PCT/US2015/041019	7/17/2015	WO 2016/011419	1/21/2016			Nationalized	Compositions for Targeting Macrophages and other CD206 High Expressing Cells and Methods of Treating and Diagnosis	Schlesinger, Larry; Bacheider, Eric; Cope, Fred
Patent Cooperation Treaty	PCT/US2015/041009	7/17/2015	WO 2016/011415	1/21/2016			Nationalized	Compounds and Compositions for Targeting Macrophages and other Mannose-Binding C-Type Lectin Receptor High Expressing Cells and Methods of Treating and Diagnosis Using Same.	Schlesinger, Larry; Bacheider, Eric; Cope, Fred Jariour, Wael N.

PATENT

REEL: 042680 FRAME: 0438

RECORDED: 06/12/2017